Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 23 | 2026Roche and Sanofi Q1 ’26 Earnings; Topline Ph3 PIONEER TEENS Data; Hims & Hers Expands Integration to LillyDirect; Amgen Management ChangesPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, Topics Apr 22 | 2026CMS Delays Launch of Obesity BALANCE Model; Sanofi’s Tzield Receives Black Box Warning Following Pediatric Label Expansion; Beta Bionics Q1 ’26 Earnings; Pfizer’s Ecnoglutide Injection Available for Pre-Order in ChinaPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Apr 21 | 2026Pfizer’s Andrew Baum to Depart at the End of 2026; Amazon Launches AOM Management Program; Dexcom Opens First OUS CGM Manufacturing Site; Kailera Closes IPO; BioAge Reports Additional Ph1 NLRP3i Data; Abbott Wins Preliminary Injunction Appeal Against SinocarePurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other, Topics Apr 20 | 2026New Foundayo DTC Ad; Roche Shares New INN for CT-388; April CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Apr 17 | 2026Early Foundayo Prescription Trends; Kailera Announces IPO Pricing; AZ’s Partner Initiates Ph1 FIH Study of Monthly Dual Agonist; ViCentra Eliminates Waiting Period for Kailedo Patch Pump in Select EU CountriesPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Apr 16 | 2026Lilly Shares ACHIEVE-4 Topline Data and Receives CNPV for Orforglipron in T2DM; Novo Initiates AMAZE 2; Pfizer and D&D Pharmatech Research Service Agreement; Abbott Q1 ’26 Earnings; Novartis Ph1 HF StudyPurchase Blast
$599
Posted in: Other, Topics Apr 15 | 2026Regeneron Targets PNPLA3 for MASH; Aurigene and Alveus Extend CollaborationPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 15 | 2026Obesity Spotlight Series: 2026 to Set AZ’s TrajectoryPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Apr 15 | 2026FDA Publishes Foundayo Letter of Approval; Novo Partners with OpenAI for AI Drug Development; Sana T1DM Collaboration; Corbus Doses Last Patient in Ph1 CB1 StudyPurchase Blast
$599
Posted in: Other, Topics Apr 13 | 2026Kailera Valued at $1.9B as it Eyes IPO; Diamyd Discontinues DIAGNODE-3 TrialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Apr 10 | 2026Ex-Novo Exec Joins BI; MetaVia Doses First Patient in Final Part of Ph1 Obesity Study; LifeMD to Offer Foundayo; Modular Medical Receives FDA Clearance for Pump Patch; MiniMed Pump RecallPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 09 | 2026Foundayo Available in the US; FDA Issues Warning Letters for Unapproved GLP-1RAs; EMA Wegovy Label Update; Novo’s Lotte Bjerre Knudsen Departs; 23andMe Study Identifies Genetic Connection for GLP-1RA-Induced Weight Loss; Noom PartnershipPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 07 | 2026Novo HD Wegovy Launches in US; Novo Initiates Second AMAZE Knee OA Study; AZ Advances Novel Obesity Asset; Insulet’s Pump Featured in TV Show; Ascletis Selects Next Obesity AssetPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Apr 06 | 2026Foundayo Analysis: The Oral AOM Market is Heating UpPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Apr 04 | 2026FDA Updates Compounding Policies; Skye Doses First Patient in Ph2 Expansion Study; Aspect Receives $79M in FundingPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Apr 01 | 2026Whoop Raises Series G with Participation from Abbott; Currax Partners with Peek; Wegovy NICE Recommendation; Novo Cuts Bloomington Workforce; Ambrosia Raises Series BPurchase Blast
$599
Posted in: GLP-1RA, Topics Apr 01 | 2026Orforglipron Approved by FDA as “Foundayo”Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 31 | 2026Novo Pilots Subscription-Based Model for Wegovy; Novo Initiates Another Ph3 Zenagamtide Study; Inventiva Q4 ‘25 Earnings; Beta Bionics Launches New Data Analysis Feature; Vaxess Rebrands as Terrestrial BioPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other, Topics Mar 30 | 2026Kailera Files IPO; Diamyd Data Disappoints; Insilico and Lilly Partner for AI Drug Discovery; EMA Approves Bayer’s Kerendia for HFpEF; Gan & Lee QW Insulin; Roche Ph1 CAD Study; Lilly Ph3 TOGETHER-PsA ResultsPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other, Topics Mar 27 | 2026Novo’s Awiqli Receives FDA Approval; Oral Wegovy Discount Price Extension; Kailera Ph2 Obesity Study; Ionis Cuts TRYNGOLZA WAC PricePurchase Blast